Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Delayed Onset of Thrombotic Microangiopathy (TMA) upon Prolonged Carfilzomib Therapy in Multiple Myeloma: A Case Report and Comprehensive Review.
Pharmaceuticals (Basel)
December 2024
Department of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, 1097 Budapest, Hungary.
Background: Thrombotic microangiopathy (TMA) is a potentially life-threatening complication associated with carfilzomib, a proteasome inhibitor approved for treating multiple myeloma. TMA typically presents within the initial months of treatment; however, delayed onset is rare and poses significant diagnostic challenges.
Methods: We conducted a retrospective analysis of the medical records of a 47-year-old Caucasian woman diagnosed with IgA kappa myeloma who developed signs and symptoms consistent with TMA eleven months after the initiation of carfilzomib therapy and already in ongoing very good partial remission.
SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy.
Front Immunol
January 2025
Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Introduction: Multiple myeloma (MM) is an uncontrolled plasma cell proliferation in the bone marrow, leading to immune dysregulation with impaired humoral immune responses. Conversely, cellular-based responses play a vital role in MM patients. However, the extent and duration of cellular-induced protection remain unclear to date.
View Article and Find Full Text PDFInternational Staging System Status and Trend of Relapse in Multiple Myeloma Cases in a Tertiary Level Health Care.
Mymensingh Med J
January 2025
Dr Md Mahbubul Alam, Junior consultant (Medicine), National Gastroliver Institute and Hospital, Dhaka, Bangladesh; E-mail:
Multiple myeloma (MM) is a haematological neoplasm of mature B-cell lineage origin. It is characterized by abnormal clonal proliferation of plasma cells and presence of monoclonal protein in serum and / or urine. This study was conducted to observe the International Staging System (ISS) status and trends of relapse.
View Article and Find Full Text PDFDistinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System.
J Appl Lab Med
December 2024
The Binding Site, part of Thermo Fisher Scientific, Rochester, MN, United States.
Background: Therapeutic monoclonal antibodies (t-mAbs) may interfere with electrophoresis-based methods used to monitor multiple myeloma (MM), which can create inaccurate results. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry is an alternative to gels distinguishing between endogenous M-proteins and t-mAbs based on molecular mass.
Methods: Serum samples (n = 109) from 34 MM patients receiving Dara-KRd were collected 14 or 28 days postdaratumumab administration.
Atypical Presentation of Plasmacytoma in a Young Woman.
Cureus
October 2024
Internal Medicine, Campbell University School of Osteopathic Medicine, Lillington, USA.
Article Synopsis
- * Subsequent tests, including a bone marrow biopsy and PET scan, led to the diagnosis of a solitary plasmacytoma (SP), which is a rare tumor type, highlighting the unusual presentation of the condition in a patient experiencing chest pain.
- * The patient received localized radiation therapy for treatment, while also being monitored for the potential progression to multiple myeloma (MM), emphasizing the need for ongoing surveillance in such cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!